Generation and application of human induced-stem cell memory T cells for adoptive immunotherapy

Taisuke Kondo, Yuki Imura, Shunsuke Chikuma, Sana Hibino, Setsuko Omata-Mise, Makoto Ando, Takashi Akanuma, Mana Iizuka, Ryota Sakai, Rimpei Morita, Akihiko Yoshimura

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Adoptive T-cell therapy is an effective strategy for cancer immunotherapy. However, infused T cells frequently become functionally exhausted, and consequently offer a poor prognosis after transplantation into patients. Adoptive transfer of tumor antigen-specific stem cell memory T (TSCM) cells is expected to overcome this shortcoming as TSCM cells are close to naïve T cells, but are also highly proliferative, long-lived, and produce a large number of effector T cells in response to antigen stimulation. We previously reported that activated effector T cells can be converted into TSCM-like cells (iTSCM) by coculturing with OP9 cells expressing Notch ligand, Delta-like 1 (OP9-hDLL1). Here we show the methodological parameters of human CD8+ iTSCM cell generation and their application to adoptive cancer immunotherapy. Regardless of the stimulation by anti-CD3/CD28 antibodies or by antigen-presenting cells, human iTSCM cells were more efficiently induced from central memory type T cells than from effector memory T cells. During the induction phase by coculture with OP9-hDLL1 cells, interleukin (IL)-7 and IL-15 (but not IL-2 or IL-21) could efficiently generate iTSCM cells. Epstein–Barr virus-specific iTSCM cells showed much stronger antitumor potentials than conventionally activated T cells in humanized Epstein–Barr virus transformed-tumor model mice. Thus, adoptive T-cell therapy with iTSCM offers a promising therapeutic strategy for cancer immunotherapy.

Original languageEnglish
Pages (from-to)2130-2140
Number of pages11
JournalCancer Science
Volume109
Issue number7
DOIs
Publication statusPublished - 2018 Jul 1

Fingerprint

Adoptive Immunotherapy
Stem Cells
T-Lymphocytes
Cell- and Tissue-Based Therapy
Immunotherapy
Interleukin-15
Interleukin-7
Neoplasms
Oncogenic Viruses
Adoptive Transfer
Neoplasm Antigens
Antigen-Presenting Cells
Coculture Techniques

Keywords

  • adoptive immunotherapy
  • cytokine
  • Epstein–Barr virus
  • immunological memory
  • methodological study

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Generation and application of human induced-stem cell memory T cells for adoptive immunotherapy. / Kondo, Taisuke; Imura, Yuki; Chikuma, Shunsuke; Hibino, Sana; Omata-Mise, Setsuko; Ando, Makoto; Akanuma, Takashi; Iizuka, Mana; Sakai, Ryota; Morita, Rimpei; Yoshimura, Akihiko.

In: Cancer Science, Vol. 109, No. 7, 01.07.2018, p. 2130-2140.

Research output: Contribution to journalArticle

Kondo, T, Imura, Y, Chikuma, S, Hibino, S, Omata-Mise, S, Ando, M, Akanuma, T, Iizuka, M, Sakai, R, Morita, R & Yoshimura, A 2018, 'Generation and application of human induced-stem cell memory T cells for adoptive immunotherapy', Cancer Science, vol. 109, no. 7, pp. 2130-2140. https://doi.org/10.1111/cas.13648
Kondo, Taisuke ; Imura, Yuki ; Chikuma, Shunsuke ; Hibino, Sana ; Omata-Mise, Setsuko ; Ando, Makoto ; Akanuma, Takashi ; Iizuka, Mana ; Sakai, Ryota ; Morita, Rimpei ; Yoshimura, Akihiko. / Generation and application of human induced-stem cell memory T cells for adoptive immunotherapy. In: Cancer Science. 2018 ; Vol. 109, No. 7. pp. 2130-2140.
@article{0872d1f1170c48b39d546091c908cf02,
title = "Generation and application of human induced-stem cell memory T cells for adoptive immunotherapy",
abstract = "Adoptive T-cell therapy is an effective strategy for cancer immunotherapy. However, infused T cells frequently become functionally exhausted, and consequently offer a poor prognosis after transplantation into patients. Adoptive transfer of tumor antigen-specific stem cell memory T (TSCM) cells is expected to overcome this shortcoming as TSCM cells are close to na{\"i}ve T cells, but are also highly proliferative, long-lived, and produce a large number of effector T cells in response to antigen stimulation. We previously reported that activated effector T cells can be converted into TSCM-like cells (iTSCM) by coculturing with OP9 cells expressing Notch ligand, Delta-like 1 (OP9-hDLL1). Here we show the methodological parameters of human CD8+ iTSCM cell generation and their application to adoptive cancer immunotherapy. Regardless of the stimulation by anti-CD3/CD28 antibodies or by antigen-presenting cells, human iTSCM cells were more efficiently induced from central memory type T cells than from effector memory T cells. During the induction phase by coculture with OP9-hDLL1 cells, interleukin (IL)-7 and IL-15 (but not IL-2 or IL-21) could efficiently generate iTSCM cells. Epstein–Barr virus-specific iTSCM cells showed much stronger antitumor potentials than conventionally activated T cells in humanized Epstein–Barr virus transformed-tumor model mice. Thus, adoptive T-cell therapy with iTSCM offers a promising therapeutic strategy for cancer immunotherapy.",
keywords = "adoptive immunotherapy, cytokine, Epstein–Barr virus, immunological memory, methodological study",
author = "Taisuke Kondo and Yuki Imura and Shunsuke Chikuma and Sana Hibino and Setsuko Omata-Mise and Makoto Ando and Takashi Akanuma and Mana Iizuka and Ryota Sakai and Rimpei Morita and Akihiko Yoshimura",
year = "2018",
month = "7",
day = "1",
doi = "10.1111/cas.13648",
language = "English",
volume = "109",
pages = "2130--2140",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Generation and application of human induced-stem cell memory T cells for adoptive immunotherapy

AU - Kondo, Taisuke

AU - Imura, Yuki

AU - Chikuma, Shunsuke

AU - Hibino, Sana

AU - Omata-Mise, Setsuko

AU - Ando, Makoto

AU - Akanuma, Takashi

AU - Iizuka, Mana

AU - Sakai, Ryota

AU - Morita, Rimpei

AU - Yoshimura, Akihiko

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Adoptive T-cell therapy is an effective strategy for cancer immunotherapy. However, infused T cells frequently become functionally exhausted, and consequently offer a poor prognosis after transplantation into patients. Adoptive transfer of tumor antigen-specific stem cell memory T (TSCM) cells is expected to overcome this shortcoming as TSCM cells are close to naïve T cells, but are also highly proliferative, long-lived, and produce a large number of effector T cells in response to antigen stimulation. We previously reported that activated effector T cells can be converted into TSCM-like cells (iTSCM) by coculturing with OP9 cells expressing Notch ligand, Delta-like 1 (OP9-hDLL1). Here we show the methodological parameters of human CD8+ iTSCM cell generation and their application to adoptive cancer immunotherapy. Regardless of the stimulation by anti-CD3/CD28 antibodies or by antigen-presenting cells, human iTSCM cells were more efficiently induced from central memory type T cells than from effector memory T cells. During the induction phase by coculture with OP9-hDLL1 cells, interleukin (IL)-7 and IL-15 (but not IL-2 or IL-21) could efficiently generate iTSCM cells. Epstein–Barr virus-specific iTSCM cells showed much stronger antitumor potentials than conventionally activated T cells in humanized Epstein–Barr virus transformed-tumor model mice. Thus, adoptive T-cell therapy with iTSCM offers a promising therapeutic strategy for cancer immunotherapy.

AB - Adoptive T-cell therapy is an effective strategy for cancer immunotherapy. However, infused T cells frequently become functionally exhausted, and consequently offer a poor prognosis after transplantation into patients. Adoptive transfer of tumor antigen-specific stem cell memory T (TSCM) cells is expected to overcome this shortcoming as TSCM cells are close to naïve T cells, but are also highly proliferative, long-lived, and produce a large number of effector T cells in response to antigen stimulation. We previously reported that activated effector T cells can be converted into TSCM-like cells (iTSCM) by coculturing with OP9 cells expressing Notch ligand, Delta-like 1 (OP9-hDLL1). Here we show the methodological parameters of human CD8+ iTSCM cell generation and their application to adoptive cancer immunotherapy. Regardless of the stimulation by anti-CD3/CD28 antibodies or by antigen-presenting cells, human iTSCM cells were more efficiently induced from central memory type T cells than from effector memory T cells. During the induction phase by coculture with OP9-hDLL1 cells, interleukin (IL)-7 and IL-15 (but not IL-2 or IL-21) could efficiently generate iTSCM cells. Epstein–Barr virus-specific iTSCM cells showed much stronger antitumor potentials than conventionally activated T cells in humanized Epstein–Barr virus transformed-tumor model mice. Thus, adoptive T-cell therapy with iTSCM offers a promising therapeutic strategy for cancer immunotherapy.

KW - adoptive immunotherapy

KW - cytokine

KW - Epstein–Barr virus

KW - immunological memory

KW - methodological study

UR - http://www.scopus.com/inward/record.url?scp=85049337759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049337759&partnerID=8YFLogxK

U2 - 10.1111/cas.13648

DO - 10.1111/cas.13648

M3 - Article

C2 - 29790621

AN - SCOPUS:85049337759

VL - 109

SP - 2130

EP - 2140

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 7

ER -